1000 Participants Needed

Registry for T-Cell Lymphoma

Recruiting at 26 trial locations
SH
AM
Overseen ByAlison Moskowitz, MD
Age: Any Age
Sex: Any
Trial Phase: Academic
Sponsor: Memorial Sloan Kettering Cancer Center
Must be taking: Systemic therapy
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to collect and analyze information to better understand T-cell lymphoma, a type of cancer affecting the immune system. Researchers will use the data to find ways to improve treatment outcomes for those with this condition. The trial seeks individuals diagnosed with specific types of T-cell or natural killer (NK) cell lymphoma, particularly those currently receiving systemic therapy (treatment affecting the entire body). As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to advancements in therapy.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, if you have mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, or primary cutaneous acral CD8+ T-cell lymphoma, you must be on systemic therapy (treatment that affects the entire body).

Why are researchers excited about this trial?

Researchers are excited about this trial because it aims to gather comprehensive data on people with T-cell lymphoma, which could lead to breakthroughs in understanding the disease. Unlike current treatments such as chemotherapy and targeted therapies that directly attack cancer cells, this registry focuses on collecting detailed information to identify patterns, outcomes, and potential new treatment pathways. By analyzing this collected data, researchers hope to discover insights that could lead to more effective and personalized treatments in the future.

Who Is on the Research Team?

SH

Steven Horwitz, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Are You a Good Fit for This Trial?

Inclusion Criteria

You have provided written authorization.
You have or are willing to obtain sufficient tumor tissue for analysis.
You have a long-term overproduction of natural killer cells.
See 7 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Data Collection

Participants' clinical characteristics and treatment outcomes are collected and stored in a secure database

10 years

Follow-up

Participants are monitored for safety and effectiveness after data collection

1 year

What Are the Treatments Tested in This Trial?

Interventions

  • Registry for T-cell Lymphoma

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Participants with T-Cell LymphomaExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials
1,998
Recruited
602,000+